S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
NASDAQ:NYMX

Nymox Pharmaceutical - NYMX Stock Forecast, Price & News

$0.44
-0.01 (-2.21%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.43
$0.47
50-Day Range
$0.28
$0.74
52-Week Range
$0.19
$2.10
Volume
127,815 shs
Average Volume
49,261 shs
Market Capitalization
$40.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NYMX stock logo

About Nymox Pharmaceutical (NASDAQ:NYMX) Stock

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Stock News Headlines

NYMOX Appeals Deficiency Letter
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
NYMOX Updates Shareholders
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
NYMOX Receives Deficiency Letter from NASDAQ
Executives Buy Around $5M Of 4 Penny Stocks
Nymox Announces Closing of $6.4 Million Financing
Nymox Direct Offering
Nymox Announces $5 Million Registered Direct Offering
See More Headlines
Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Company Calendar

Last Earnings
11/14/2022
Today
2/05/2023
Next Earnings (Estimated)
3/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NYMX
Employees
3
Year Founded
N/A

Profitability

Net Income
$-12,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.01) per share

Miscellaneous

Free Float
41,637,000
Market Cap
$40.09 million
Optionable
Optionable
Beta
0.71

Key Executives

  • Paul Averback
    Chairman, President & Chief Executive Officer
  • Randall J. Lanham
    COO, Secretary, Director & General Counsel
  • Russell I. Thomson
    Vice President-Quality & Regulatory Affairs













NYMX Stock - Frequently Asked Questions

How have NYMX shares performed in 2023?

Nymox Pharmaceutical's stock was trading at $0.3233 at the beginning of 2023. Since then, NYMX shares have increased by 37.0% and is now trading at $0.4429.
View the best growth stocks for 2023 here
.

When is Nymox Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our NYMX earnings forecast
.

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Co. (NASDAQ:NYMX) released its quarterly earnings data on Monday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter.

What other stocks do shareholders of Nymox Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC).

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

Who are Nymox Pharmaceutical's major shareholders?

Nymox Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $0.44.

How much money does Nymox Pharmaceutical make?

Nymox Pharmaceutical (NASDAQ:NYMX) has a market capitalization of $40.09 million. The biopharmaceutical company earns $-12,540,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The official website for the company is www.nymox.com. The biopharmaceutical company can be reached via phone at (800) 936-9669, via email at info@nymox.com, or via fax at 514-332-2227.

This page (NASDAQ:NYMX) was last updated on 2/5/2023 by MarketBeat.com Staff